IR Searcher

基本データ

【業種】: 医薬品
【市場】: プライム（内国株式）
【決算期】: 3月
【会社設立】
【上場】: 1949.5
【直近決算日】: 2025-05-12（4Q）
【決算予定日】: 2025-07-28 (15:30)

【時価総額】: 2兆2298億円
【PBR】: 2.72倍
【配当利回り(予)】: 2.63%

企業概要

当社グループは、医療用医薬品の研究開発から製造、販売までを行う製薬企業であり、シオノギファーマやUMNファーマなど、多数の関係会社を持つ。
主な事業分野としては、感染症、精神・神経疾患、がんとワクチンに焦点を当て、高脂血症治療薬や抗うつ薬、抗インフルエンザ薬といった処方医薬品が含まれる。
当社は、「インチュニブ」や「サインバルタ」、「ゾフルーザ」などの主要な製品を展開しており、さらに新規治療薬の研究やCOVID-19関連の医薬品開発にも注力している。
また、2030年を見据えた新しいプラットフォーム構築を通じて、創薬型製薬企業からケアプロバイダーへの変革を目指している。

業績修正履歴

年度	タイプ	日付	売上高	営業利益	経常利益	純利益
2023-03	新規	2022-05-11	400,000	120,000	168,000	136,000
	変更	2022-10-24	410,000(⬆)	120,000(→)	174,000(⬆)	142,000(⬆)
	変更	2023-01-30	421,000(⬆)	147,000(⬆)	210,000(⬆)	170,000(⬆)
2024-03	新規	2023-05-10	450,000	150,000	192,500	155,000
2025-03	新規	2024-05-13	455,000	160,000	200,000	163,000
	変更	2024-10-28	460,000(⬆)	165,000(⬆)	206,000(⬆)	171,000(⬆)
今期	新規	2025-05-12	530,000	175,000	222,000	180,000

通期四半期別

売上高

経常利益

純利益

通期四半期別

決算期	四半期	売上高	営業利益	経常利益	純利益	1株当たり純利益	営業利益率	経常利益率	売上高/前年比	営業利益/前年比	経常利益/前年比	純利益/前年比
	予想	530,000	175,000	222,000	180,000	211.59	33.02%	41.89%	20.93%	11.75%	10.59%	6.17%
2025-03	4	438,268	156,603	200,750	169,534	200.36	35.73%	45.81%	0.7%	2.1%	1.2%	5.6%
	3	333,600	129,224	155,877	133,336	157.3	38.74%	46.73%	-1%	-6.9%	-5.2%	5.5%
	2	213,970	75,869	93,833	82,872	97.74	35.46%	43.85%	-7.2%	-22.7%	-18.8%	-8.1%
	1	97,586	28,110	36,525	30,307	108.07	28.81%	37.43%	-10.7%	-39.7%	-34.4%	-28.2%
2024-03	4	435,081	153,310	198,283	160,575	558.51	35.24%	45.57%	2%	2.9%	-10%	-13%
	3	336,821	138,737	164,487	126,439	435.89	41.19%	48.84%	-0.5%	-5.3%	-17.3%	-19.9%
	2	230,542	98,106	115,603	90,198	308.65	42.55%	50.14%	52.9%	247.6%	70.1%	57.1%
	1	109,312	46,585	55,704	42,214	144.62	42.62%	50.96%	52.2%	275%	38.2%	22.6%
2023-03	4	426,684	149,003	220,332	184,496	621.31	34.92%	51.64%	27.3%	35.1%	74.5%	62.6%
	3	338,347	146,473	198,786	157,773	527.81	43.29%	58.75%	54.1%	142.4%	165.8%	123.1%
	2	150,779	28,224	67,978	57,407	190.21	18.72%	45.08%	3.9%	-33.8%	33.7%	8.3%
	1	71,839	12,421	40,310	34,426	115.17	17.29%	56.11%	4.2%	-33.9%	75.7%	6.9%
2022-03	4	335,138	110,312	126,268	113,439	378.75	32.92%	37.68%	12.8%	-6.1%	-11.7%	1.2%
	3	219,626	60,422	74,784	70,731	235.51	27.51%	34.05%	-2.1%	-42.5%	-37.6%	-20.6%
	2	145,085	42,664	50,832	53,023	176.24	29.41%	35.04%	-2.3%	-26.8%	-27.5%	1.3%
	1	68,965	18,794	22,941	32,198	106.94	27.25%	33.26%	-3.4%	-34.2%	-30.5%	31.4%
2021-03	4	297,177	117,438	143,018	112,061	365.03	39.52%	48.13%	-10.9%	-10.1%	-9.8%	-8.3%
	3	224,419	102,201	116,830	86,073	279.9	45.54%	52.06%	-11.9%	-4.2%	-5.5%	-8.7%
	2	148,452	55,308	67,189	49,382	160.83	37.26%	45.26%	-9.3%	-12.5%	-4.9%	-9.3%
	1	71,402	25,617	30,063	21,539	70.88	35.88%	42.1%	-11.6%	-19.1%	-14.9%	-20.7%
2020-03	4	334,958	125,231	151,751	121,295	392.8	37.39%	45.3%	-7.9%	-9.6%	-8.9%	-8.6%
	3	253,514	99,249	114,899	90,844	292.78	39.15%	45.32%	-4.4%	1.9%	-0.6%	-3.7%
	2	160,877	58,161	65,305	51,616	165.78	36.15%	40.59%	-4.4%	1.5%	-6.8%	-10.8%
	1	79,225	28,957	32,401	24,418	78.43	36.55%	40.9%	-10.5%	4.7%	-14.6%	-23.4%
2019-03	4	363,721	138,537	166,575	132,759	424.31	38.09%	45.8%	5.5%	20.2%	20.1%	21.9%
	3	265,242	97,423	115,649	94,344	300.95	36.73%	43.6%	0.7%	8.1%	9.7%	18.3%
	2	168,203	57,304	70,077	57,896	184.28	34.07%	41.66%	-2.3%	2.8%	6.8%	15%
	1	88,524	27,646	37,941	31,892	101.45	31.23%	42.86%	18%	72.9%	80.1%	99.2%
2018-03	4	344,667	115,219	138,692	108,866	342.71	33.43%	40.24%	1.7%	6.5%	12.7%	29.8%
	3	263,362	90,124	105,471	79,727	250.2	34.22%	40.05%	2.7%	2.7%	15.9%	18%
	2	172,172	55,756	65,592	50,336	157.9	32.38%	38.1%	11%	25.9%	55.6%	61.3%
	1	75,023	15,988	21,071	16,010	50.22	21.31%	28.09%	2.5%	-11.4%	26.3%	27.7%
2017-03	4	338,890	108,178	123,031	83,879	259.88	31.92%	36.3%	9.3%	18.3%	22%	25.8%
	3	256,533	87,719	90,970	67,541	208.4	34.19%	35.46%	13.5%	34%	36.7%	62.1%
	2	155,101	44,288	42,147	31,198	95.82	28.55%	27.17%	12.2%	30.5%	21.1%	45.9%
	1	73,158	18,036	16,685	12,536	38.5	24.65%	22.81%	14.6%	43.9%	14.3%	29.8%
2016-03	4	309,973	91,406	100,869	66,687	204.83	29.49%	32.54%	13.1%	81.5%	29.5%	51.4%
	3	225,923	65,456	66,542	41,669	127.99	28.97%	29.45%	12.8%	81.5%	28.7%	58.7%
	2	138,279	33,933	34,791	21,386	65.69	24.54%	25.16%	6.5%	49.4%	10.7%	120.2%
	1	63,863	12,533	14,602	9,657	29.66	19.62%	22.86%	1.8%	55.7%	7.1%	-6.4%

決算期	四半期	売上高	営業利益	経常利益	純利益	1株当たり純利益	営業利益率	経常利益率	売上高/前年比	営業利益/前年比	経常利益/前年比	純利益/前年比
2025-03	4	104,668	27,379	44,873	36,198	43.06	26.16%	42.87%	6.52%	87.87%	32.78%	6.04%
	3	119,630	53,355	62,044	50,464	59.56	44.6%	51.86%	12.56%	31.32%	26.92%	39.25%
	2	116,384	47,759	57,308	52,565	-10.33	41.04%	49.24%	-4%	-7.3%	-4.33%	9.55%
	1	97,586	28,110	36,525	30,307	108.07	28.81%	37.43%	-10.7%	-39.7%	-34.4%	-28.2%
2024-03	4	98,260	14,573	33,796	34,136	122.62	14.83%	34.39%	11.23%	476.01%	56.86%	27.74%
	3	106,279	40,631	48,884	36,241	127.24	38.23%	46%	-43.34%	-65.64%	-62.63%	-63.89%
	2	121,230	51,521	59,899	47,984	164.03	42.5%	49.41%	53.57%	226.02%	116.49%	108.8%
	1	109,312	46,585	55,704	42,214	144.62	42.62%	50.96%	52.2%	275%	38.2%	22.6%
2023-03	4	88,337	2,530	21,546	26,723	93.5	2.86%	24.39%	-23.53%	-94.93%	-58.15%	-37.43%
	3	187,568	118,249	130,808	100,366	337.6	63.04%	69.74%	151.63%	565.89%	446.13%	466.78%
	2	78,940	15,803	27,668	22,981	75.04	20.02%	35.05%	3.7%	-33.8%	-0.8%	10.35%
	1	71,839	12,421	40,310	34,426	115.17	17.29%	56.11%	4.2%	-33.9%	75.7%	6.9%
2022-03	4	115,512	49,890	51,484	42,708	143.24	43.19%	44.57%	58.76%	227.43%	96.59%	64.34%
	3	74,541	17,758	23,952	17,708	59.27	23.82%	32.13%	-1.88%	-62.13%	-51.75%	-51.74%
	2	76,120	23,870	27,891	20,825	69.3	31.36%	36.64%	-1.21%	-19.61%	-24.87%	-25.21%
	1	68,965	18,794	22,941	32,198	106.94	27.25%	33.26%	-3.4%	-34.2%	-30.5%	31.4%
2021-03	4	72,758	15,237	26,188	25,988	85.13	20.94%	35.99%	-10.66%	-41.36%	-28.94%	-14.66%
	3	75,967	46,893	49,641	36,691	119.07	61.73%	65.35%	-17.99%	14.13%	0.09%	-6.47%
	2	77,050	29,691	37,126	27,843	89.95	38.53%	48.18%	-5.64%	1.67%	12.83%	2.37%
	1	71,402	25,617	30,063	21,539	70.88	35.88%	42.1%	-11.6%	-19.1%	-14.9%	-20.7%
2020-03	4	81,444	25,982	36,852	30,451	100.02	31.9%	45.25%	-17.3%	-36.8%	-27.64%	-20.73%
	3	92,637	41,088	49,594	39,228	127	44.35%	53.54%	-4.54%	2.42%	8.83%	7.63%
	2	81,652	29,204	32,904	27,198	87.35	35.77%	40.3%	2.48%	-1.53%	2.39%	4.59%
	1	79,225	28,957	32,401	24,418	78.43	36.55%	40.9%	-10.5%	4.7%	-14.6%	-23.4%
2019-03	4	98,479	41,114	50,926	38,415	123.36	41.75%	51.71%	21.12%	63.83%	53.29%	31.83%
	3	97,039	40,119	45,572	36,448	116.67	41.34%	46.96%	6.41%	16.73%	14.28%	24.01%
	2	79,679	29,658	32,136	26,004	82.83	37.22%	40.33%	-17.98%	-25.42%	-27.82%	-24.24%
	1	88,524	27,646	37,941	31,892	101.45	31.23%	42.86%	18%	72.9%	80.1%	99.2%
2018-03	4	81,305	25,095	33,221	29,139	92.51	30.87%	40.86%	-1.28%	22.66%	3.62%	78.35%
	3	91,190	34,368	39,879	29,391	92.3	37.69%	43.73%	-10.1%	-20.87%	-18.32%	-19.13%
	2	97,149	39,768	44,521	34,326	107.68	40.94%	45.83%	18.56%	51.49%	74.85%	83.94%
	1	75,023	15,988	21,071	16,010	50.22	21.31%	28.09%	2.5%	-11.4%	26.3%	27.7%
2017-03	4	82,357	20,459	32,061	16,338	51.48	24.84%	38.93%	-2.01%	-21.16%	-6.6%	-34.7%
	3	101,432	43,431	48,823	36,343	112.58	42.82%	48.13%	15.73%	37.78%	53.77%	79.18%
	2	81,943	26,252	25,462	18,662	57.32	32.04%	31.07%	10.11%	22.67%	26.12%	59.11%
	1	73,158	18,036	16,685	12,536	38.5	24.65%	22.81%	14.6%	43.9%	14.3%	29.8%
2016-03	4	84,050	25,950	34,327	25,018	76.84	30.87%	40.84%	14.01%	81.48%	31.23%	40.56%
	3	87,644	31,523	31,751	20,283	62.3	35.97%	36.23%	―	―	―	―
	2	74,416	21,400	20,189	11,729	36.03	28.76%	27.13%	―	―	―	―
	1	63,863	12,533	14,602	9,657	29.66	19.62%	22.86%	1.8%	55.7%	7.1%	-6.4%

4507 塩野義製薬 企業サイト Yahooファイナンス 日経新聞 株探 四季報

4507 塩野義製薬　企業サイト　　　Yahooファイナンス　日経新聞　株探　四季報　